Our periodic round-up of financings in the biotech sector is led by an impressive nine-figure round for UK vaccines developer Vicebio, with GC Therapeutics, Genespire, and 858 Therapeutics
Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.
UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA.